Word: inhibitor
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...drug could dramatically boost the effectiveness of standard colorectal-cancer chemotherapy, shrinking tumors in more than a fifth of otherwise hopeless cases. Says Sloan-Kettering's Saltz: "The fact that we got a 20% response rate is staggering." What is happening, he surmises, is that the growth-factor inhibitor weakens the tumor enough for chemotherapy to finish...
...Buoyed by those results, Saltz will begin testing IMC-C225 in less advanced patients this summer. And because combination therapy seemed to work so well, he is combining the EGFR inhibitor with not one but two chemotherapy agents to pack a triple punch...
...Fusion inhibitors are the rising stars of the entry inhibitor group. Designed to keep the HIV virus from fusing to the cell wall, fusion inhibitors include compounds called T-20 and T-1249. The first compound, T-20, appears to be at the head of the class, so to speak; researchers report low toxicity among test cases, and relatively mild side effects like soreness and inflammation at the injection site, dizziness and nausea. For the needle-phobic, T-20 may cause a few problems - patients are required to inject themselves twice a day. But for most, even multiple injections...
...John's wort came into its own in 1984, when the German government classified it as an MAO inhibitor, on the basis of in-vitro studies, and approved its use as a mild, natural antidepressant. Sales took off both in Germany, where St. John's wort easily outsells prescription drugs like Prozac, and in the U.S., where concoctions of the herb, sold under such labels as Mood Support and Brighten Up, became flagships of the booming alternative- medicine industry. Before last year's warnings that St. John's wort could interfere with other medications--notably AIDS treatments, antibiotics, cardiac drugs...
...public relations woes, Bristol-Meyers-Squibb Pharmaceuticals announced last week that it would market its AIDS drugs, Zerit and Videx, to Africa at a combined price of $1 per day. This follows closely on the heels of Merck Pharmaceuticals' announcement that it would market its drug, the protease inhibitor Crixivan, to Africa at the reduced price of $600 per year. AIDS drugs typically cost between $10,000 and $15,000 per year. Needless to say, because of these exorbitantly high prices, these drugs are out of reach for those most in need--especially those in sub-Saharan Africa, quickly becoming...